ANKLE2

Across TCGA pan-cancer cohorts, ANKLE2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANKLE2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANKLE2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANKLE2 expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ANKLE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.285	0.820	.001	55	view →
PDAC	DFS	Tertile	All	0.277	0.451	.008	27	view →
HNSC	DFS	Quartile	III,IV	0.644	0.968	.001	26	view →
OV	DFS	Median	All	1.000	0.872	.044	4	view →
LSCC	DFS	Median	II,III,IV	0.973	0.875	.015	4	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.017	4	view →
LUAD	DFS	Median	III,IV	0.767	0.341	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANKLE2–CCRCC (OS)

Open the CCRCC breakdown →